Erasca, Inc. (ERAS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $9.69: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum.
Erasca is a clinical-stage precision oncology company singularly focused on RAS/MAPK pathway-driven cancers, with two Phase 1 programs: ERAS-0015 (pan-RAS molecular glue, AURORAS-1 trial) and ERAS-4001 (pan-KRAS inhibitor, BOREALIS-1 trial). The company has no approved products... Read more
Sell if holding. Engine safety override at $9.69: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.0/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductRAS/MAPK pathway10-K Item 1A: 'all of our current product candidates and development programs are based on the RAS/MAPK pathway'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $9.69: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $8.90. Score 5.0/10, moderate confidence.
Take-profit target: $18.01 (+88.3% upside). Prior stop was $8.90. Stop-loss: $8.90.
Concentration risk — Product: RAS/MAPK pathway; Quality below floor (1.6 < 4.0).
Erasca, Inc. trades at a P/E of N/A (forward -16.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
17 analysts cover ERAS with a consensus score of 4.1/5. Average price target: $21.
What does Erasca, Inc. do?Erasca is a clinical-stage precision oncology company singularly focused on RAS/MAPK pathway-driven cancers, with two...
Erasca is a clinical-stage precision oncology company singularly focused on RAS/MAPK pathway-driven cancers, with two Phase 1 programs: ERAS-0015 (pan-RAS molecular glue, AURORAS-1 trial) and ERAS-4001 (pan-KRAS inhibitor, BOREALIS-1 trial). The company has no approved products and recorded a net loss of $124.5M in 2025 with an accumulated deficit of $892.2M since inception.